Latest filings (excl ownership)
EFFECT
Notice of effectiveness
10 May 24
424B3
Prospectus supplement
9 May 24
S-3
Shelf registration
2 May 24
8-K
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
2 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
5 Apr 24
S-8
Registration of securities for employees
6 Mar 24
8-K
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Other Events
23 Jan 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Other Events
5 Jan 24
8-K
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Sep 23
8-K
Other Events
16 Aug 23
8-K
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
3 Aug 23
424B5
Prospectus supplement for primary offering
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Departure of Directors or Certain Officers
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
424B5
Prospectus supplement for primary offering
9 Jun 23
8-K
Entry into a Material Definitive Agreement
9 Jun 23
424B5
Prospectus supplement for primary offering
8 Jun 23
8-K
Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at Elevation Oncology on track to initiate Phase 1 clinical trial in the US in the second half of 2023
5 Jun 23
8-K
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Regulation FD Disclosure
17 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
S-8
Registration of securities for employees
9 Mar 23
8-K
Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
3 Mar 23
8-K
Results of Operations and Financial Condition
6 Jan 23
Latest ownership filings
SC 13G
Frazier Life Sciences Public Fund, L.P.
9 Apr 24
4
Joseph J Ferra Jr
19 Mar 24
4
Alan B. Sandler
4 Mar 24
4
Julie M Cherrington
4 Mar 24
3
Alan B. Sandler
4 Mar 24
3
Julie M Cherrington
4 Mar 24
4
Valerie Malyvanh Jansen
20 Feb 24
4
Tammy Furlong
20 Feb 24
4
David Dornan
20 Feb 24
4
Joseph J Ferra Jr
20 Feb 24
SC 13G
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
ExodusPoint Capital Management, LP
7 Feb 24
SC 13G/A
Aisling Capital IV, LP
6 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
31 Jan 24
SC 13G
Logos Global Management LP
22 Jan 24
4
Darcy Mootz
22 Jan 24
3
Darcy Mootz
22 Jan 24
SC 13G
Farallon Capital Partners, L.P.
22 Jan 24
SC 13G/A
Qiming U.S. Healthcare GP II, LLC
9 Jan 24
SC 13G
Empery Asset Management, LP
9 Jan 24
4
Joseph J Ferra Jr
19 Dec 23
4
Joseph J Ferra Jr
19 Sep 23
4
TIMOTHY P CLACKSON
5 Sep 23
4
Tammy Furlong
14 Jul 23
3
Tammy Furlong
14 Jul 23
4
Joseph J Ferra Jr
14 Jul 23
4
Colin Walsh
21 Jun 23
4
Lori Hu
21 Jun 23
4
TIMOTHY P CLACKSON
21 Jun 23
4
R Michael Carruthers
21 Jun 23
4
ANDREW N SCHIFF
21 Jun 23
4
Joseph J Ferra Jr
21 Jun 23
SC 13D/A
venBio Global Strategic Fund III, L.P.
15 Jun 23
SC 13G
ExodusPoint Capital Management, LP
9 Jun 23
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
8 Jun 23